ArticleCureus2025
Apneic Tracheal Stenting Using Femorofemoral Venoarterial Extracorporeal Membrane Oxygenation in a Coronavirus Disease 2019 (COVID-19) Patient With Critical Airway Obstruction: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palliative tracheal stenting for severe central airway obstruction in patients with coronavirus disease 2019 (COVID-19) presents a dual challenge: the imminent risk of acute asphyxia during anesthetic induction and the risk of viral transmission to healthcare professionals via aerosols. While extracorporeal membrane oxygenation (ECMO) can serve as a safety bridge to facilitate apneic interventions, conventional venovenous ECMO may not be feasible in patients with superior vena cava (SVC) compression. Femorofemoral venoarterial ECMO (VA-ECMO) is an alternative; however, it carries a substantial risk of differential hypoxia, particularly in patients with poor native lung function. We report a case of a 41-year-old woman with COVID-19 pneumonia and critical tracheal stenosis (luminal diameter 2 mm) caused by mediastinal lymphadenopathy. Given the prohibitive risk of airway collapse and the need for aerosol containment, she underwent successful apneic tracheal stent placement under femorofemoral VA-ECMO support. This approach was employed because SVC compression precluded upper body cannulation, and differential hypoxia was managed using a multifaceted physiological strategy without circuit modification. A combination of high-flow ECMO, deep anesthesia, pharmacologic cardiac output suppression, and anemia correction effectively mitigated the risk of differential hypoxia. This case demonstrates that femorofemoral VA-ECMO is a safe and effective option for facilitating apneic high-risk airway procedures, simultaneously ensuring airway security and infection control when conventional strategies are insufficient. Further case accumulation is needed to determine the validity and generalizability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.